@tt.hiline I’m very lengthy IOVA and stay dedicated.However here’s what you should know to find out the reply to your query (and I don’t know the solutions). Is the routine that IOVA stated would be the purpose for the fatality used throughout the complete IOVA platform or is it distinctive to NSCLC remedy? See quote under:“The incident may very well be probably associated to the non-myeloablative lymphodepletion pre-conditioning routine, Iovance (IOVA) added.”If it isn’t used outdoors of NSCLC, then the market is certainly overreacting. Whether it is, then you definitely would want to do extra analysis on the specifics of this case (which you’ll’t) and whether or not they apply broadly.The truth that FDA is permitting different research to proceed is encouraging and appears to counsel this isn’t a systemic challenge impacting the complete platform. The PDUFA nonetheless being on monitor doesn’t really let you know a lot since IOVA already has submitted the whole lot for the BLA.